ABOUT
HealthTech Arkansas helps to drive innovation for the ten largest hospitals and health systems in Arkansas, which is accomplished through accelerator programs and internal innovation programming.
Our internal innovation programming is focused on helping our state’s healthcare provider organizations to harvest, organize and develop ideas for new innovations from their own clinicians and administrators. We do that through a variety of specific programs focused on solving real problems and challenges (clinical and administrative in nature) through the development and commercialization of intellectual property to be owned by the provider organization.
HeartX – the annual accelerator currently focused on cardiovascular technologies - guarantees at least two hospital pilot projects or clinical trials for each early-stage company admitted to the program. In addition to the guaranteed pilots, participating companies receive upfront investment from the HealthTech Arkansas Fund.
Our accelerator targets three areas of healthcare innovation: digital health (software), medical devices and diagnostic platforms. Our program is for providers and by providers, so we seek technologies that can improve our providers’ operations by improving quality of care, enhancing efficiencies, reducing costs, etc. In fact, our providers choose the companies invited to participate in the program each year.
Our accelerator is virtual, so there’s no requirement to be in Arkansas other than when you’ll be here to work with your provider partners on your pilot projects or clinical trials. In addition to the guaranteed pilots, participating companies receive upfront investment capital through a SAFE or convertible note.
Applications are now closed for the HeartX Accelerator.
SymBiosis and HealthTech Arkansas have partnered to launch the biophyle Trial Accelerator, a program designed to elevate healthcare innovations in Arkansas by connecting accomplished, clinical-stage biotherapeutic innovations to Arkansas healthcare providers through clinical trial opportunities or commercialization training programs.
The program offers two tracks: Track 1 is for clinical-stage companies with at least one novel biotherapeutic asset in the oncology, immunology, or cardiometabolic space and Track 2 is for Arkansas-based life science researchers interested in learning how to move their research towards commercialization.